Behind the hustle and bustle of the crypto market, Injective is quietly changing the rules of the game. The native EVM is about to launch, which means developers can build high-performance, cross-chain DeFi applications in an Ethereum-compatible environment. More than 40 dApps and infrastructure providers are already prepared to join the ecosystem, reflecting not only technological advantages but also indicating that the underlying structure of on-chain finance is being reshaped.
The trends in institutional investment further confirm the value of Injective. Pineapple Financial, a company listed on the New York Stock Exchange, has raised $100 million for open market purchases of INJ, while the Injective ETF is also set to launch in the U.S. market, allowing both institutions and retail investors to participate in a compliant manner. This influx of capital enhances liquidity while providing solid support for token value.
What is most anticipated is Injective's layout for RWA (real-world assets). Stocks, gold, foreign exchange, and digital asset bonds have already been tokenized on-chain, and even Nvidia stocks have been tokenized. This allows investors to participate directly in traditional financial markets on-chain, enjoying transparent, efficient, and composable financial tools.
Injective is paving the way with both technology and capital, connecting traditional finance and the on-chain world. As the market focuses on hot projects, it quietly occupies a strategic high ground in financial infrastructure.
The above content is only personal analysis and does not constitute any investment advice.
